Lifeplex Science raises $5.3M Series A for anti-aging RNA therapeutics development. The biotech company plans clinical trials for its osteoarthritis treatment in 2027.
Amount Raised
$5.3 Million
Round Type
Series A
SeoulBiotechnologyHealth CareTherapeuticsInvestors
Description
Lifeplex Science, a developer of anti-aging RNA therapeutics, has raised $5.3 million in Series A funding. The round was led by multiple investors including Korea Development Bank, Medytox Venture Investment, and Murex Partners. The company plans to use the funds for clinical trials of its osteoarthritis RNA therapeutic and develop three additional pipeline candidates targeting obesity, kidney disease, and heart disease. Lifeplex Science was founded by Professor Jinhong Kim and operates a microRNA degradation platform for treating age-related diseases.
Quick answer
Lifeplex Science raised $5.3 Million in a Series A round, dated November 13, 2026. Investors: Korea Science & Technology Holdings, Quad Asset Management, Myriad Partners, Mirae Science & Technology Holdings, Murex Partners, Medytox Venture Investment and Korea Development Bank. Lifeplex Science is based in Seoul, Seoul, South Korea.
- How much did Lifeplex Science raise?
- Lifeplex Science raised $5.3 Million in a Series A round on November 13, 2026.
- Who invested in Lifeplex Science?
- Korea Science & Technology Holdings, Quad Asset Management, Myriad Partners, Mirae Science & Technology Holdings, Murex Partners, Medytox Venture Investment and Korea Development Bank are named as investors in this round.
- What does Lifeplex Science do?
- Lifeplex Science is a biotech company developing anti-aging RNA therapeutics using a microRNA degradation platform to treat age-related diseases.
- Where is Lifeplex Science based and how big is it?
- Lifeplex Science is based in Seoul, Seoul, South Korea.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Lifeplex Science that raised within 45 days of this round, from Fundz verified event records.
- Orakl Oncology raised $34M (Series A) on November 12, 2026.
- VectorY raised $83M on November 11, 2026.
- Neurosterix raised $105M (Series B) on November 11, 2026.
- Oyster Therapeutics raised $60M (Series A) on November 10, 2026.
- SRTD biotech raised $35M (Seed) on November 9, 2026.
- BioVie raised $4.7M (Post-IPO Equity) on November 6, 2026.
Who to call at Lifeplex Science, and when
A new round usually means Lifeplex Science is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Lifeplex Science raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Lifeplex Science, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Lifeplex Science. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Lifeplex Science raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansLifeplex Science raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.